Fondazione Italiana Linfomi - Ets

This study is testing a drug called tislelizumab as a first treatment for older adults with Hodgkin lymphoma who are not healthy enough for standard chemotherapy. The goal is to see if this single, immunotherapy drug can effectively control the cancer with fewer side effects. Res…

This study is testing if adding an immunotherapy drug (atezolizumab) to a standard chemotherapy regimen (BEGEV) works better to prepare patients for a stem cell transplant. It is for adults whose Hodgkin's lymphoma has returned or not responded to their first treatment. The goal …

This study is testing whether a combination of two drugs (rituximab and golcadomide) can control aggressive lymphoma in older, frail patients who are too weak for standard chemotherapy. The goal is to see if this chemotherapy-free approach can keep the cancer from progressing whi…

This study is testing whether adding the drug daratumumab to two existing medications (bortezomib and dexamethasone) can help control plasmablastic lymphoma that has returned or hasn't responded to previous treatments. The trial will enroll about 28 adults whose cancer cells show…

This large, late-stage trial is testing if adding a drug called obinutuzumab to standard radiotherapy works better at controlling early-stage follicular lymphoma and keeping it from coming back. It will enroll 190 adults with previously untreated, early-stage disease. The main go…

This study is testing whether a combination of two drugs, mosunetuzumab and zanubrutinib, can help control follicular lymphoma that has returned or stopped responding to prior treatment. It will involve about 56 adults who have had at least one prior therapy. The main goal is to …

This study is testing whether adding a targeted drug called loncastuximab tesirine after a short course of chemotherapy can help control relapsed mantle cell lymphoma in patients whose cancer stopped responding to or who couldn't tolerate BTKi drugs. About 49 patients will receiv…

This study is testing whether a 6-month personalized health plan can improve the quality of life for people who survived lymphoma. The plan includes nutrition advice, physical activity guidance, and follow-up care. Researchers will compare the results of participants who follow t…

This study aims to understand how doctors treat a rare type of skin cancer called cutaneous T-cell lymphoma in real-world practice. Researchers will look back at the medical records of 400 patients who received treatments between 2016 and 2023. The goal is to see which treatments…

This study aims to understand how standard treatments for slow-growing lymphoma affect the quality of life of patients aged 70 and older. Researchers will observe 150 patients receiving treatments like immunotherapy or radiation, tracking their well-being through questionnaires b…

This study aims to understand how specific genetic changes in a gene called MYC affect the course and treatment response of two aggressive types of B-cell lymphoma. Researchers will analyze tissue samples and medical records from 200 patients who have already been treated, lookin…

This study aims to better understand plasmablastic lymphoma, a rare type of blood cancer, by looking back at the medical records of 200 past patients. Researchers will collect information on how patients were diagnosed, what treatments they received, and how they fared over time.…

This study aims to understand if muscle loss or a patient's overall health status can predict how well someone responds to CAR-T cell therapy for B-cell lymphoma. Researchers will observe 130 adult patients already scheduled to receive this treatment. They will measure muscle mas…

This study is observing how newer antibody treatments work for B-cell non-Hodgkin lymphoma in everyday Italian clinics. It will follow 1,500 patients already scheduled to receive these approved treatments to collect real-world data on effectiveness, side effects, and long-term ou…

This study looks back at 20 years of data from Italian patients with primary cardiac lymphoma, a rare cancer that starts in the heart. Researchers are analyzing how patients were treated and what factors affected their survival and response to therapy. The goal is to better under…

This study aims to find biological markers in blood and tissue that can help doctors choose the most effective first treatment for advanced follicular lymphoma. Researchers will analyze samples from 654 patients who previously participated in a treatment trial. The goal is to cre…